Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

DNTHDNTH
12 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in Dianthus Therapeutics, Inc.

CITADEL ADVISORS LLC holds 974,911 shares of DNTH (Dianthus Therapeutics, Inc.), worth $95M as of 2026-Q2. The position was decreased (-39.5% shares). DNTH represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$95M

Current Shares

974,911

Total Value Change

+$93.6M

Total Shares Change

+869,350

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
974,911
-39.5%
$95M0.0%$97.48
0
2026-Q1
Increased
1.6M
+50.7%
$135.2M0.0%$55.39
42
2025-Q4
Increased
1.1M
+5.5%
$44.1M0.0%$40.96
31
2025-Q3
Increased
1M
+52.4%
$39.9M0.0%$39.55
41
2025-Q2
Increased
665,044
+41.2%
$12.4M0.0%$17.63
37
2025-Q1
Increased
470,880
+11.6%
$8.5M0.0%$19.99
31
2024-Q4
Increased
422,038
+611.7%
$9.2M0.0%$21.50
45
2024-Q3
New
59,301
-
$1.6M0.0%$27.24
35
2024-Q2
Exited
0
-100.0%
$00.0%$25.88
0
2024-Q1
New
24,829
-
$744,8700.0%$30.00
34
2023-Q4
Exited
0
-100.0%
$00.0%$10.40
0
2023-Q3
New
105,561
-
$1.4M0.0%$13.67
35

Other major holders of DNTH: FMR LLC, BlackRock, Inc., WELLINGTON MANAGEMENT GROUP LLP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used